[CAS NO. 2377113-41-0] EG-011
PRODUCTS SPECIFICATIONS [2377113-41-0]
DESCRIPTION [2377113-41-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 482.53 |
| Molecular Formula | C28H26N4O4 |
| SMILES | O=C(N1CCCC(C1)N2C(C3=NC=CC=C3N(CC4=CC=C(C=C4)OC5=CC=CC=C5)C2=O)=O)C=C |
Summary
In Vitro
EG-011 (500 nM, 2 μM; 72h) causes a dose-dependent increase in cell death (20-55%) in lymphoma cell lines (OCI-LY-19 and REC1). EG-011 (1, 10 mM; for 24h, 48h) has no cytotoxicity in PBMCs from two healthy donors
[1]
.
EG-011 (500 nM, 5 μM; 24h) causes an increase in actine polymerization in EG-011 sensitive (VL51) and not in resistant (Z138) cell lines at 4, 8 and 24h with both concentrations
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
EG-011 (200 mg/kg; i.p.; 5 days per week) delays tumor growth (Day 6, Day 7, Day 9) and tumor weight in female NOD-SCID mice with the MCL REC-1 cell line. EG-011-treated tumors are 2.2-fold smaller than controls (P<0.001)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] E. Gaudio, et al. EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVOANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. Hematological OncologyVolume 37: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019.
- [2] Filippo Spriano, et al. Abstract 1817: EG-011 is a first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity. Cancer Res (2022) 82 (12_Supplement): 1817.
- [3] F. Spriano, et al. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. European Journal of Cancer 174S1 (2022) S3-S128.